A 50-year-old Japanese woman who had previously undergone laparoscopic nephrectomy for right renal cell carcinoma underwent cord blood transplantation for AML from a 4/6 HLA-matched unrelated donor. The conditioning regimen included fludarabine, BU and TBI. GVHD prophylaxis consisted of tacrolimus and mycophenolate mofetil. Engraftment was achieved on day 26, and CR was confirmed on day 37. As she did not develop acute or chronic GVHD, the tacrolimus was tapered off 2 months after cord blood transplantation. At 4 months after cord blood transplantation, she was readmitted because of a 1-month history of fever, pharyngeal pain and loss of appetite. A physical examination disclosed a temperature of 37.9 1C, a tongue mass and bilateral cervical lymph node enlargement. Hematological examination revealed a WBC count of 6.4 Â 10 9 /l with no blasts, Hb concentration of 8.5 g per 100 ml and a plt count of 8 Â 10 9 /l. Blood tests showed elevated aspartate aminotransferase (49 IU/l), alanine aminotransferase (31 IU/l), alkaline phosphatase (771 IU/l) and lactate dehydrogenase (326 IU/l). A BM aspirate showed hypocellular marrow, of which 3.8% was made up of blasts. A computed tomography (CT) scan revealed a thickened pharyngeal wall, diffuse interstitial thickenings with ground-glass opacities along the bronchovascular bundles in both lungs, multiple low-density areas in the liver, bowel wall thickening, bilateral cervical lymph node enlargement, bilateral pleural effusion and ascites (Figures 1a-c) . Whole-body FDG-PET showed increased uptake in the upper pharynx, a thickened bowel wall, multiple nodular lesions in the liver and systemic lymph nodes. Multiple focal lesions within diffuse abnormal uptake were also detected throughout both lungs ( Figure 2a ). Histological examinations of both the right inguinal lymph node and tongue mass revealed a diffuse and polymorphous infiltrative process consisting of a spectrum of lymphoid cells ranging from small and mature to atypical large cells, within a background of inflammatory cells. Immunohistochemical staining showed atypical large lymphoid cells that were positive for CD20 and CD79a and negative for CD3, CD5 and CD10, indicating the B-cell nature of the proliferation. In situ hybridization for Epstein-Barr encoding small nuclear RNA was positive in these cells. A PCR study of the lymph node for Ig heavy chain rearrangement identified the presence of a polyclonal B-cell population. Real-time quantitative PCR for EBV-DNA of the peripheral blood found that its expression was elevated (6600 copies/10 6 WBC). Thus, the patient was diagnosed with polymorphic PTLD. She received rituximab at a dose of 375 mg/m 2 once a week for six consecutive weeks. Her general condition dramatically improved after the initiation of the treatment. After two courses of rituximab, although a CT scan showed stable disease (Figures 1d-f) , an FDG-PET scan showed marked reduction of FDG-avid lesions with residual foci in the upper Figure 2 Positron emission tomography scans using 18F-fluorodeoxyglucose (FDG-PET) at diagnosis and after two courses of rituximab. (a) An FDG-PET showed increased uptake in the upper pharynx, the thickened bowel wall, multiple nodular lesions in the liver and systemic lymph nodes. Multiple focal lesions were also detected within an area of diffuse abnormal uptake that extended throughout both lungs. (b) An FDG-PET scan showed marked reduction of FDG-avid lesions with residual foci in the upper pharynx and both lungs, indicating a partial response. pharynx and both lungs, indicating a partial response (Figure 2b) . Subsequently, almost all lesions were found to have disappeared on a follow-up CT scan, and tests for EBV-DNA were negative after six courses of rituximab therapy. Although she died from a relapse of AML 5 months after the completion of rituximab therapy, there was no evidence of a relapse of PTLD.
In recent years, FDG-PET has been developed as a new diagnostic technique for the management of lymphoma. Clinical experience indicates that FDG-PET scan is more sensitive and specific than contrast-enhanced CT imaging for intermediate-to high-grade non-Hodgkin's lymphoma and Hodgkin's disease. The major advantage of PET over conventional imaging resides in its ability to detect disease in the absence of morphological abnormalities. Moreover, FDG-PET scanning is helpful for evaluating treatment response, especially in patients with persistent lesions on CT scans. However, the value of PET scanning for low-grade lymphomas is not well established. 7 Although PTLD is related to lymphoma, the heterogeneity of PTLD prevents direct extrapolation of these results to cases of PTLD, especially those of the polymorphic type. Although PTLD arising after SOT and allo-SCT share many common features, such as extranodal involvement, EBV positivity and B-cell phenotype, there are some notable differences between them. PTLD arising after allo-SCT develops earlier and is more likely to present with fulminant and disseminated disease. 8 EBV is found in nearly 100% of cases of PTLD after allo-SCT; whereas, up to 15% of cases of PTLD after SOT are EBV-negative. The majority of PTLD cases arising after SOT are of recipient origin; whereas, those arising after allo-SCT are of donor origin. 8 Although withdrawal of immunosuppressive therapy is the first-line therapy for PTLD after SOT, this treatment is ineffective in most cases after allo-SCT because of the severe immunosuppression caused by the conditioning regimen and graft manipulation. 1 Although FDG-PET has been shown to be useful in patients with PTLD after SOT, 2-6 the value of FDG-PET for the management of PTLD after allo-SCT has not been clarified. In the current case, all disease sites seen on CT studies were identified using a FDG-PET scan. Suspicious but equivocal areas of thickened bowel walls and interstitial shadows in both lungs observed on CT examination showed pronounced FDG activity. Normal-sized lymph nodes on the CT scan showed pathological FDG uptake on PET imaging. FDG-PET was able to show an earlier response than conventional cross-sectional imaging. Accurate identification of the extent of disease is important in PTLD, as the number of involved sites is an independent prognostic factor. 9 In addition, early evaluation of therapeutic efficacy is essential to identify patients who are suitable for less-toxic treatment, especially considering the high treatment-related mortality of PTLD patients receiving chemotherapy.
1 Thus, our observation suggests that FDG-PET is an efficient imaging modality for the staging and therapeutic monitoring of polymorphic PTLD after allo-SCT. Further study of the role of FDG-PET in the management of PTLD is warranted.
